ReviewJournal of personalized medicine2022

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.

Mauro Ceccanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.